
Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus
The novel active agent HY-133, which was developed by HYpharm and prepared for clinical trials in collaboration with the German Center for Infection Research (DZIF) and universities in Tübingen, Munich, Münster and Greifswald, received approval […]